Switching from sulfonylurea to sitagliptin among type 2 diabetic patients in combination with metformin or pioglitazone.
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000003584
- Lead Sponsor
- Hokuriku Incretin-based Therapy Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients satisfying any of the following criteria; 1) receiving or having received sitagliptin 2) having neural diseases (including clinically overt cerebral infarction) but diabetic neuropathy 3) having arrhythmia or heart failure 4) having more than moderate renal dysfunction (sCr > 1.5 mg/dl in men, > 1.3 mg/dl in women) 5) having severe liver dysfunction 6) having malignancy 7) being pregnant, or breast-feeding 8) having any of contraindications for sitagliptin 9) having contraindications for both metformin and pioglitazone 10) suspected as pheochromocytoma, or having allergic history against glucagon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method